comparemela.com

Latest Breaking News On - C michael gibson - Page 4 : comparemela.com

Significant MACE Reduction Not Observed With Novel ApoA-I Formulation

Topline results were announced from the phase 3 AEGIS-II trial evaluating CSL112 (apolipoprotein A-I [human]) on reducing the risk of MACE.

C michael gibsonAmerican college of cardiology scientific sessionsHarvard medical schoolBaim institute for clinical researchAmerican collegeCardiology scientific sessionsBaim instituteClinical researchHarvard medical

AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis

CSL112, a human plasma-derived apolipoprotein A-I, failed to reduce 90-day MACE, according to top-line results.

United statesC michael gibsonAmerican college of cardiologyMd baim institute for clinical researchHarvard medical schoolAmerican collegeBaim instituteClinical research

Significant MACE Reduction Not Observed With Novel ApoA-I Formulation

Topline results were announced from the phase 3 AEGIS-II trial evaluating CSL112 (apolipoprotein A-I [human]) on reducing the risk of MACE.

C michael gibsonHarvard medical schoolBaim institute for clinical researchAmerican college of cardiology scientific sessionsAmerican collegeCardiology scientific sessionsBaim instituteClinical researchHarvard medical

Andrea Bocelli cancels Boston concert just before showtime over health challenges

Bocelli told the crowd at the TD Garden that he did his best to sing, but couldn't.

United statesBoston universitySan franciscoBoston gardenAndrea bocelliNealj rileyVeronica bertiC michael gibsonBoston globeWells fargo centerPhiladelphia thursday

Asundexian s Lack of Efficacy Sinks OCEANIC-AF

Bayer says the phase III trial was stopped early because the novel Factor XIa inhibitor was inferior to apixaban for stroke risk.

United statesC michael gibsonData monitoring committeeAmerican heart associationIndependent data monitoring committee

vimarsana © 2020. All Rights Reserved.